Sign in to see all reviews and comparisons. It's Free!
By clicking Sign In with Social Media, you agree to let PAT RESEARCH store, use and/or disclose your Social Media profile and email address in accordance with the PAT RESEARCH Privacy Policy and agree to the Terms of Use.
ScreenPoint develops Deep Learning and image analysis technology for automated reading of mammograms and digital breast tomosynthesis with solutions such as Transpara Decision Support, Transpara Score, and Transpara CAD.
Category
AI-based Medical Imaging – Breast Imaging
Features
• Deep learning • Image analysis technology • Digital breast tomosynthesis • Transpara Decision Support • Transpara Score • Transpara CAD • Breast cancer detection • mammograms reading
License
Proprietary
Price
Contact for Pricing
Pricing
Subscription
Free Trial
Available
Users Size
Small (<50 employees), Medium (50 to 1000 Enterprise (>1001 employees)
Company
ScreenPoint Medical
What is best?
• Deep learning • Image analysis technology • Digital breast tomosynthesis • Transpara Decision Support • Transpara Score • Transpara CAD • Breast cancer detection
What are the benefits?
• Interactive decision support • Eliminates false positives • Concurrent information provision • Automatic mammogram reading • Intelligent context exploitation
PAT Rating™
Editor Rating
Aggregated User Rating
Rate Here
Ease of use
7.6
6.1
Features & Functionality
7.6
8.0
Advanced Features
7.6
8.0
Integration
7.6
7.9
Performance
7.6
7.1
Customer Support
7.6
7.0
Implementation
10
Renew & Recommend
8.3
Bottom Line
ScreenPoint develops Deep Learning and image analysis technology for automated reading of mammograms and digital breast tomosynthesis with solutions such as Transpara Decision Support, Transpara Score, and Transpara CAD.
7.6
Editor Rating
7.8
Aggregated User Rating
10 ratings
You have rated this
ScreenPoint develops Deep Learning and image analysis technology for automated reading of mammograms and digital breast tomosynthesis with solutions such as Transpara Decision Support, Transpara Score, and Transpara CAD. It exploits the latest methods in the rapidly evolving field of machine learning, combining these with very large well curated digital image databases and a thorough understanding of the physics of mammogram image formation and the practicalities of the clinical deployment of mammographic image analysis.
Transpara decision Support is a novel concept for computer aided detection of breast cancer developed by the founders of ScreenPoint. It recognizes the fact that radiologists need decision support and not just marks to support search for abnormalities, for both soft tissue lesions and calcifications. Readers can probe suspicious image regions for decision support. Transpara™ Score categorizes every mammogram on a 10-point scale based on image analysis and deep learning algorithms. If no potential abnormalities are found a low score is assigned.
When there are suspicious findings a higher score is assigned. Transpara™ CAD provides calcification CAD marks that can be viewed on both the mammography reading station and the Transpara™ Tablet Viewer. Additionally, very few soft-tissue lesion marks are shown with extremely low false positive rates. The Transpara DBT application provides information to significantly improve reading workflow for DBT on breast reading workstations. With Transpara, the reader can automatically jump to a relevant DBT slice in both the CC and MLO 3D data, by simply clicking on a suspicious region in a synthetic mammogram. Transpara DBT marks the lesion in the relevant slices and provides quantitative decision support for individual soft tissue lesions and calcifications.
By clicking Sign In with Social Media, you agree to let PAT RESEARCH store, use and/or disclose your Social Media profile and email address in accordance with the PAT RESEARCH Privacy Policy and agree to the Terms of Use.